Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ: NTLA) showcased its innovative CRISPR/Cas9 technology during the ASGCT Annual Meeting, presenting promising data on NTLA-5001 for acute myeloid leukemia (AML) and NTLA-2002 for hereditary angioedema (HAE). The proprietary process for NTLA-5001 enables multiple gene edits in T cells, leading to enhanced therapeutic potential. Data revealed >98% efficiency in gene editing with minimal adverse translocations. NTLA-2002 demonstrated a sustained 90% reduction in kallikrein activity, indicating significant efficacy in reducing HAE attack rates. IND submissions for both drug candidates are anticipated in 2021.
Intellia Therapeutics (NASDAQ: NTLA) announced key updates in its pipeline for Q1 2020, focusing on its CRISPR/Cas9 technology. The company plans to submit INDs for its lead therapies: NTLA-2001 for transthyretin amyloidosis by mid-2020, NTLA-5001 for acute myeloid leukemia in 1H 2021, and NTLA-2002 for hereditary angioedema in 2H 2021. Intellia ended the quarter with a cash position of $250 million, expecting a runway through the end of 2021. However, research and development expenses rose, leading to a net loss of $31.8 million compared to $21.9 million in Q1 2019.
Summary not available.
Summary not available.
Summary not available.